Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].

Zhongguo shi yan xue ye xue za zhi - 1 Apr 2012

He Xiang-Meng, Zhang Ling-Yan, Li Ying

Abstract excerpt

This study was aimed to investigate the therapeutic effect of two molecular targeted therapeutic drugs, tyrosine kinase inhibitors gefitinib and lapatinib, on JAK2 V617F positive myeloproliferative disorders (MPD). The human leukemia cell line (HEL cell line) carrying JAK2 V617F mutation was treated with gefitinib (0.5, 1, 5, 10, 25 µmol/L) and lapatinib (0.5, 1, 2, 4, 8, 16 µmol/L) respectively. MTT method was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Lapatinib

Share to Myeloproliferative Disorders

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22541101

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

[Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].PMID 22541101Read ↗

[leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].Semantic proximity Read ↗

[Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].Semantic proximity Read ↗

[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].Semantic proximity Read ↗

[Effect of Interferon Combined with Thalidomid on HEL Cell Apoptosis and JAK2V617F Mutation Gene Expression].Semantic proximity Read ↗

[Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].Semantic proximity Read ↗

[Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].Semantic proximity Read ↗

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].Semantic proximity Read ↗

[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.